SFDA Approves Registration Of Skyclarys For Treating Friedreich’s Ataxia In Adults And Adolescents

The Saudi Food and Drug Authority (SFDA) has given the green light for Skyclarys (Omaveloxolone), a drug previously recognised as an orphan drug under their Orphan Drug Program. This medication is designed to treat Friedreich’s ataxia in individuals aged 16 and older. The condition is a rare genetic disorder that affects movement and significantly impacts the quality of life.

Omaveloxolone works by activating the nuclear factor erythroid 2-related factor 2 (Nrf2). This protein plays a crucial role in managing the body's response to oxidative stress. In Friedreich’s ataxia patients, Nrf2 activity is often reduced, which worsens the disease. By boosting Nrf2, Omaveloxolone helps protect nerves by reducing oxidative stress.

SFDA's approval of Skyclarys came after evaluating its safety and effectiveness according to regulatory standards. Clinical trials showed significant improvements in patients' conditions. The main study revealed that those treated with the drug had lower modified Friedreich’s Ataxia Rating Scale (mFARS) scores compared to placebo recipients after 48 weeks, proving its efficacy in slowing disease progression.

Long-term data further supports the benefits of Skyclarys, showing sustained positive effects for up to three years. This contrasts with the expected natural decline associated with Friedreich’s ataxia, highlighting the ongoing clinical advantages of this treatment.

While effective, Skyclarys may cause side effects. Commonly reported issues include elevated liver enzymes, headaches, back pain, nausea, vomiting, appetite loss, and weight loss. The studies also noted interactions with grapefruit juice and drugs affecting the CYP3A4 enzyme.

Orphan Drug Program Benefits

The SFDA's Orphan Drug Program aims to improve access to treatments for rare diseases that often lack options. An orphan drug targets conditions affecting fewer than five people per 10,000 in Saudi Arabia. The program offers benefits like pre-submission meetings, priority review for registration, and scientific consultations from the Drug Sector.

This initiative aligns with Saudi Vision 2030's goal to enhance healthcare quality by promoting pharmaceutical innovation and addressing unmet medical needs. For more details on orphan drugs guidelines, visit the SFDA website.

With inputs from SPA